Dihexa is an angiotensin-IV-derived research peptide that has been studied in animal models for cognitive effects. Important: some foundational mechanism papers have been retracted. Dihexa has no human clinical trials. All dosage information below reflects preclinical research only.
Evidence Status
Dihexa has no human clinical trial data. Foundational papers proposing an HGF/c-Met synaptogenesis mechanism were retracted. The compound remains in preclinical research status. No established safe or effective human dose exists.
Doses Used in Animal Research
Preclinical studies have used doses ranging from 1–10 mg/kg in rodent models. These cannot be directly extrapolated to human dosing. No validated human dose conversion exists.
Research Context
Dihexa was developed as an angiotensin IV analogue. It was proposed to activate the HGF/c-Met signalling pathway — a mechanism now under scrutiny following paper retractions. Current research interest focuses on angiotensin receptor interactions.